Diagnostics in Hymenoptera venom allergy: current concepts and developments with special focus on molecular allergy diagnostics
- PMID: 28503403
- PMCID: PMC5406443
- DOI: 10.1007/s40629-017-0014-2
Diagnostics in Hymenoptera venom allergy: current concepts and developments with special focus on molecular allergy diagnostics
Abstract
Background: The high rate of asymptomatic sensitization to Hymenoptera venom, difficulty in correctly identifying Hymenoptera and loss of sensitization over time make an accurate diagnosis of Hymenoptera venom allergy challenging. Although routine diagnostic tests encompassing skin tests and the detection of venom-specific IgE antibodies with whole venom preparations are reliable, they offer insufficient precision in the case of double sensitized patients or in those with a history of sting anaphylaxis, in whom sensitization cannot be proven or only to the presumably wrong venom.
Methods: Systematic literature research and review of current concepts of diagnostic testing in Hymenoptera venom allergy.
Results and discussion: Improvements in diagnostic accuracy over recent years have mainly been due to the increasing use of molecular allergy diagnostics. Detection of specific IgE antibodies to marker and cross-reactive venom allergens improves the discrimination between genuine sensitization and cross-reactivity, and this provides a better rationale for prescribing venom immunotherapy. The basophil activation test has also increased diagnostic accuracy by reducing the number of Hymenoptera venom sensitizations overlooked with routine tests. This paper reviews current concepts of diagnostic testing in Hymenoptera venom allergy and suggests fields for further development.
Keywords: Basophil activation test; Diagnostic algorithm; Recombinant allergens; Skin test; cross-reactive carbohydrate determinants.
Conflict of interest statement
T. Jakob has received research grants and speakers honoraria from Thermo Fischer/Phadia Freiburg, Germany and Uppsala, Sweden in addition to research support from ALK-Abello, Allergy Therapeutics, Allergopharma, Cormetics Europe and Novartis. D. Rafei-Shamsabadi declares that he has no competing interests. E. Spillner is co-founder of PLS-Design. S. Müller has received speakers honoraria from Novartis, Bencard and Travel reimbursement from ALK Abello.
Figures
References
-
- Schäfer T. Epidemiology of insect venom allergy. Allergo J. 2009;18:353–358. doi: 10.1007/BF03362108. - DOI
-
- Przybilla B, Ruëff F, Walker A, Räwer HC, Aberer W, Bauer CP, et al. Diagnosis and therapy of bee und wasp venom allergy. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), des Ärzteverbandes Deutscher Allergologen (ÄDA), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), der Deutschen Dermatologischen Gesellschaft (DDG) und der Deutschen Gesellschaft für Kinderund Jugendmedizin (DGKJ) in Zusammenarbeit mit der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI) und der Schweizerischen Gesellschaft für Allergologie und Immunologie (SGAI) Allergo J. 2011;20:318–339. doi: 10.1007/BF03362543. - DOI
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
